BOCOM INTL: Raised target price of SINO BIOPHARM (01177) to HK$8, maintain "buy" rating.

date
21/07/2025
avatar
GMT Eight
ReXin Pharmaceutical will become a wholly-owned subsidiary of Chinese biopharmaceuticals, and its main research and management team, along with its dual antibody, ADC, and other technology platforms, will join Chinese biopharmaceuticals.
BOCOM INTL released a research report stating that the efforts of SINO BIOPHARM (01177) in acquisition and cost reduction have shown significant results. The adjusted net profit forecast for 2025-27 has been raised by 10-11%, and the target price has been raised to HK$8. The "Buy" rating is maintained, with short-term catalysts including potential BD authorization opportunities for the company's self-developed pipeline. The report states that the group announced its intention to acquire 95.09% equity of Li Xin Pharmaceutical for a transaction value not exceeding US$951 million. Excluding Li Xin Pharmaceutical's estimated cash and bank deposits of approximately US$450 million on the delivery date, the net payment amount to be made for the acquisition is approximately US$501 million. After the completion of this transaction, Li Xin Pharmaceutical will become a wholly-owned subsidiary of SINO BIOPHARM, and its main research and management team, along with its dual antibody, ADC, and other technology platforms, will join SINO BIOPHARM.